Laurina

Quick links to important sections

Laurina

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laurina

Quick Facts about Laurina

Property Description
Active ingredients Desogestrel, Ethinyl Estradiol
Form Oral tablet (monophasic)
Pharmacological class Estrogen and Progestin Combinations
Common use Contraception (birth control)
Origin Synthetic steroidal hormones

Defining Laurina: A Combination Oral Contraceptive

Laurina is a prescription-only combined hormonal contraceptive (COC) formulated to prevent pregnancy. Its sole definitive purpose is to serve as a reliable method of birth control for women, a function established for the medication. This medicine is characterized as a combined contraceptive because it utilizes both an estrogen and a progestin component, administered in the form of an oral tablet. This systemic hormonal product provides a consistent, daily-administered method of family planning.


Composition and Hormonal Classification

The active ingredients in Laurina are the synthetic hormones Desogestrel and Ethinyl Estradiol. These compounds are chemically manufactured, confirming the drug's synthetic origin. Desogestrel is specifically recognized as a third-generation progestin, which differentiates it from oral contraceptives using older progestational compounds. This formulation is classified as monophasic, meaning the concentration of both active hormones remains constant in each active pill. The formulation of Ethinyl Estradiol and Desogestrel is characterized by its consistent hormonal concentration and classification for preventing pregnancy. The final dosage form is a solid oral tablet, which contains these active ingredients along with inert solid oral dosage excipients.


High-Level Function and General Benefit

The general benefit of Laurina is providing effective protection against unintended pregnancy. The presence of the combined synthetic hormones acts to achieve hormonal regulation, primarily by inhibiting ovulation, which is the release of an egg from the ovary. This comprehensive hormonal action is what defines the medicine's role and effectiveness as a dependable contraceptive option.

Regulatory References

  1. Oral Contraceptive Pills - StatPearls - NCBI Bookshelf

What side effects are possible with Laurina?

Possible Side Effects and Safety Information

Laurina's safety profile, based on regulatory documentation, defines possible effects by system-organ class (SOC) and frequency of occurrence. The majority of reported effects are classified as common or uncommon, while the most significant risks are considered rare but serious.

Classification Examples of Officially Documented Effects
Common Nausea, headache, abdominal pain, mood changes (including depressed mood), weight increase, and breast pain or tenderness.
Uncommon/Rare Vomiting, diarrhea, migraine, fluid retention, rash, urticaria, change in libido, or contact lens intolerance.

Serious Adverse Reactions

The most clinically significant risks highlighted in regulatory labels are rare Thromboembolic Events, which include Venous Thromboembolism (VTE) (such as Deep Vein Thrombosis and Pulmonary Embolism) and Arterial Thromboembolism (ATE) (such as stroke and myocardial infarction). Other serious documented risks include an increase in Blood Pressure and the rare development of Hepatic Neoplasia (liver tumors).

Exposure- and Population-Related Safety

Some safety patterns are linked to the duration of use. Irregular bleeding or spotting is noted as common and generally self-resolving during the first three months of use. The risk of developing hepatic tumors is associated with long-term exposure, typically defined as four or more years of use. Laurina is strictly contraindicated in individuals with a high risk of vascular events, pre-existing liver tumors, or known estrogen-sensitive malignancies. Caution is also advised for use in women with well-controlled hypertension or diabetes.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Laurina (Desogestrel/Ethinyl Estradiol) is characterized by a low acute toxicity profile based on regulatory documentation. Acute overdosage is generally not likely to be life-threatening, and the hormonal components have been officially assessed as having no serious harmful effects reported in acute settings. The officially documented clinical manifestations of taking too much Laurina are transient and primarily include gastrointestinal symptoms. These documented signs are nausea and vomiting. A further recognized presentation is withdrawal bleeding (vaginal bleeding), which may be slight. A specific population consideration is the manifestation of slight vaginal bleeding noted in young girls following accidental ingestion.


Required Emergency Actions

Immediate actions are mandated by regulatory authorities following any suspected or confirmed overdosage. Individuals must seek immediate medical attention and/or contact a poison control center for official guidance. This urgent care is required to initiate appropriate management, as no specific antidote is known for this combination of hormones. Management, therefore, relies on symptomatic and supportive treatment and may include monitoring of vital signs under professional supervision. These actions are procedural steps required by regulatory documentation.

Therapeutic Uses of Laurina

What Laurina Treats: Main Uses and Benefits

Laurina is generally applied across therapeutic domains that involve specific reproductive health goals. The medication may be considered relevant for providing both essential preventive healthcare and necessary symptomatic support for specific menstrual cycle disorders. Its primary therapeutic use is the prevention of pregnancy.


Contraception and Proactive Family Planning

The core therapeutic function is commonly used to help with the prevention of unintended pregnancy. This long-term, daily application is applied in clinical settings that involve proactive family planning. This use generally provides support that helps maintain stability and assists with reproductive choices.

“The consistent, daily use of this medication may assist with establishing predictable cycle patterns.”

Supportive Relief for Menstrual Symptom Clusters

Beyond its primary contraceptive role, Laurina is commonly used to help with specific symptom clusters that may become intense or disruptive. It is relevant for managing symptoms that interfere with daily comfort, such as abnormally heavy or prolonged bleeding (menorrhagia) and severe pelvic pain (dysmenorrhea). This therapeutic approach may assist with maintaining a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load.

Quick Fact: Relief for Menstrual Distress
This medication is considered relevant for easing symptoms related to physical discomfort and increased physiological activity during menstrual periods.

Regulatory References

  1. NIH DailyMed Label for Desogestrel/Ethinyl Estradiol

Eligibility and Restrictions for Use

Laurina (Desogestrel/Ethinyl Estradiol) is officially defined for use by women of reproductive age for the purpose of contraception, and its eligibility is strictly determined by regulatory rules.


Contraindicated Populations (Must Not Use)

Use is strictly prohibited in females who have or have a history of certain medical conditions, as specified in official regulatory documents. These contraindications include:

  • Thromboembolic Disorders: Current or history of deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thromboembolic disease (e.g., stroke, myocardial infarction).
  • Neoplasia: Known or suspected breast carcinoma or other hormone-sensitive cancers.
  • Hepatic Function: Severe liver disease, hepatic tumors, or impaired liver function.
  • Vascular Risk: Migraine with aura, uncontrolled hypertension, diabetes mellitus with vascular involvement, and women over 35 years of age who smoke.

Restricted and Non-Recommended Use

The medication is contraindicated in pregnancy. It is not recommended for women who are breastfeeding due to documented effects on milk quality and quantity, nor is it recommended for females prior to menarche. Use is not indicated for the geriatric population (post-menopausal women). Furthermore, the medicine should be temporarily suspended prior to and shortly following major surgery involving prolonged immobilization.

What should I know about interactions with other medicines?

Laurina, a combination hormonal contraceptive, has clinically significant interactions defined by two main mechanisms: changes in drug concentration and effects on potassium levels.

Reduced Efficacy via Enzyme Induction

Concomitant use with medicines or herbal products that induce certain enzymes, primarily CYP3A4, can decrease the concentrations of the contraceptive hormones. This pharmacokinetic interaction may reduce the effectiveness of Laurina. Official labeling advises that women using strong enzyme inducers, such as certain antiepileptics or St. John’s wort, should be counseled to use a back-up or alternative method of contraception.

Risk of High Potassium

Due to the anti-mineralocorticoid activity of the progestin drospirenone, co-administration with other medicines that may increase serum potassium concentration carries an official warning for the potential risk of hyperkalemia. This includes product classes such as ACE inhibitors, Angiotensin-II receptor antagonists, potassium-sparing diuretics, heparin, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). For women on long-term treatment with these interacting agents, the official constraint is to monitor serum potassium concentration during the first treatment cycle.

Contraindicated Combinations

Laurina is contraindicated for use with Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir, due to the potential for significant elevation in liver enzyme levels.

Mechanism of Action

Modulating Central Neurotransmitter Signaling

Laurina functions primarily as an antagonist at key Dopamine D2 and Serotonin 5 HT2A receptors located in the central nervous system. This molecular interaction blocks the binding of endogenous transmitters, thereby inhibiting the activation of associated signaling pathways. Concurrently, the drug displays a multi-receptor profile, acting as a partial agonist at the 5 HT1A receptor while also antagonizing the Alpha-2 C adrenergic and 5 HT7 receptors.

This precise, multi-site engagement alters the dynamics of multiple neural circuits. At the cellular level, this mechanism modifies nerve impulse transmission rates and limits the downstream propagation of altered neurotransmitter activity. The cascade ultimately influences feedback regulation within central pathways, resulting in altered physiological activity patterns across the affected neural networks. This system-level modulation establishes the drug's overall pharmacodynamic profile.

Dosage and Administration Information

How Laurina is Used: General Administration Guidelines

Laurina is administered orally as a solid tablet and is intended for use in a fixed 28-day cyclical regimen. The standard administration protocol involves taking one tablet daily, with the cycle divided into 21 days of active tablets (e.g., containing 0.15 mg desogestrel / 0.03 mg ethinyl estradiol) followed by 7 days of inert tablets.

To ensure consistent delivery of the active ingredients, a key procedural requirement is that the tablet must be taken at approximately the same time each day. Established protocols define procedures for initiating the first pack, which may include starting on Day 1 of the menstrual period. If the regimen is started on any day other than Day 1, an additional non-hormonal method is required for the first seven days of the first cycle.

Instructions for managing the cycle specify that the tablet-free interval must not be extended beyond 7 days. If a single active tablet is missed, the general procedure is to take the last missed tablet as soon as it is remembered, then continue the regular schedule. In cases where absorption may be compromised, such as due to vomiting within 3-4 hours of intake, a new, replacement active tablet should be taken. This cyclical dosing regimen is also specified for postpubertal adolescents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Laurina

This section describes the types of official research that have been conducted for the combined hormonal ingredients in Laurina (Desogestrel and Ethinyl Estradiol), summarizing what studies have explored and what aspects remain uncertain, based on regulatory and scientific literature.


Evidence for Use in Contraception (Preventing Pregnancy)

The research foundation for this hormonal combination includes decades of data from large-scale observational studies and open-label clinical trials; these studies primarily assessed the prevention of pregnancy. Research examined outcomes related to systemic or functional imbalance required for ovulation inhibition and was conducted across wide populations of healthy, sexually active women of reproductive age.

Studies and monitoring programs describe measurements of pregnancy incidence during periods of use, which were reported to be lower when the product was used exactly as directed ("perfect use"). Evidence derived from observational settings evaluating daily-life functioning indicates that when user adherence was varied ("typical use"), the measured incidence of pregnancy was higher. The full research landscape highlights that adherence was associated with the consistency of measured outcomes in real-world use.


Evidence for Supportive Menstrual Symptom Management

The active ingredients were studied in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as severe period pain (dysmenorrhea) and abnormally heavy or prolonged bleeding (menorrhagia). The evidence base for these supportive uses includes Randomized Controlled Trials (RCTs) and systematic reviews.

Short-term RCTs typically reported patterns related to changes in pain scores and blood loss measurements during the active treatment cycles compared to pre-treatment periods. However, for these supportive uses, evidence quality varies across studies, and the certainty level for some subjective outcomes remains low, according to some scientific reviews. Follow-up durations were limited in many rigorous trials, typically observing responses over 3 to 6 treatment cycles.

Key Studies & References

  1. Effectiveness and efficacy rates of progestin-only pills: A comprehensive literature review (Includes discussion of Desogestrel's mechanism and Pearl Index)

Frequently Asked Questions (FAQ)

Common questions about Laurina (FAQ)


Q: Is Laurina considered a long-term or short-term treatment?

A: Laurina is officially indicated for contraception, a function that typically involves continuous, ongoing use for extended periods. Safety information in regulatory documents often includes discussion of effects over prolonged exposure, such as use lasting four or more years.


Q: Can Laurina cause weight gain or weight loss?

A: Based on clinical data summarized in official safety documentation, weight increase is listed as a commonly reported effect. Official documentation does not typically list weight loss as a commonly reported effect.


Q: Can Laurina be taken with common vitamins or supplements?

A: Regulatory documents list numerous prescription medicines and specific herbal products, like St. John’s wort, that may interact with Laurina. Official guidance includes the need to consult a healthcare professional regarding potential combinations with any non-prescription medicines, vitamins, or supplements due to the potential for interactions.


Q: How long does the effect of Laurina last after a dose?

A: The medicine is part of a daily regimen, meaning it is designed to be taken once daily at the same time to maintain continuous hormonal coverage. The drug is designed for continuous effectiveness, which is supported by the components' typical elimination time of approximately 24 to 28 hours.


Q: Is Laurina safe to use while breastfeeding is generally discussed in studies?

A: Official product information specifies that use of the medicine is generally restricted or not recommended during breastfeeding. This restriction is due to documented effects that the medicine can have on the quantity and quality of milk produced.


Q: Can older adults typically use Laurina?

A: Laurina is officially indicated for women of reproductive age and is not indicated for the geriatric population, which refers to post-menopausal women. Eligibility is determined by age, reproductive status, and the presence of any contraindicating health conditions.


Q: Do studies suggest Laurina causes mood changes?

A: Official safety documentation confirms that mood changes, including depressed mood, are listed as a common side effect reported in clinical data. This information is included in the adverse reaction sections of the regulatory label.


Q: How is the effectiveness of Laurina usually measured in clinical trials?

A: Clinical trials and ongoing monitoring programs that study Laurina primarily assess the prevention of pregnancy. The effectiveness is typically measured and reported by tracking the pregnancy incidence during periods of use.


Q: What happens if Laurina expires?

A: Official instructions specify that any unused or expired medication should be discarded after the expiration date according to local guidelines. Disposal should be conducted according to approved methods, often through an authorized drug take-back program.


Q: Does Laurina affect fertility in general terms?

A: The drug's primary function is to prevent pregnancy while it is being used. When the medicine is stopped, fertility typically returns within a few months, although the precise time frame can vary among individuals.


Q: Are there any common reasons people stop taking Laurina?

A: While the decision to stop is personal, discontinuation often relates to the experience of common or persistent side effects. These may include documented effects like nausea, mood changes, or irregular bleeding.


Q: Is there a list of major interactions to be aware of when taking Laurina?

A: Official labeling details several types of significant interactions. These include medicines that induce certain liver enzymes (which can reduce effectiveness), medicines that may increase serum potassium (which carries a risk of hyperkalemia), and specific Hepatitis C drug combinations (which are strictly contraindicated).


Q: What happens if I miss a dose of Laurina?

A: Official regulatory protocols describe specific instructions for managing missed active tablets. These procedures generally involve taking the last missed tablet as soon as it is remembered and may require temporary use of back-up contraception.


Q: Does Laurina affect blood pressure?

A: An increase in blood pressure is a documented potential effect and a serious risk associated with Laurina. Due to this potential, monitoring of blood pressure is often recommended by healthcare providers during the period of use.


Q: Are there special considerations for children using Laurina?

A: The medicine is not recommended before the start of menstruation (menarche). It is intended for use by postpubertal adolescents for contraception purposes.


Q: Is Laurina a controlled substance?

A: Official US government sources confirm that the medicine is not classified as a controlled substance under the Controlled Substances Act.


Q: Can Laurina be split or crushed?

A: Official instructions specify that the solid tablet is taken orally and swallowed whole as directed in the blister pack. There is no official indication that the tablets are approved for splitting or crushing.


Q: Does taking Laurina with food change how it works?

A: The official administration guidelines state that the medicine can generally be taken with or without food. Taking it with food may sometimes be suggested as a way to help reduce feelings of nausea.


Q: Is stomach upset a frequent experience for people taking Laurina?

A: Common side effects documented in official safety information include nausea and abdominal pain or stomach cramps. Other digestive issues, such as vomiting and diarrhea, are listed as uncommon or rare effects.


Q: Is it possible to develop a dependency on Laurina?

A: Laurina is not classified as a controlled substance and is not associated with the typical potential for drug dependence, either physical or psychological.


Q: What are the general guidelines for traveling with Laurina?

A: Official storage instructions require that the medicine be stored at a defined room temperature and be protected from excessive heat and moisture. The guidance is to keep the medicine in its original container when traveling to help maintain stability.


Q: Do people typically experience withdrawal symptoms if Laurina is stopped?

A: When the drug is stopped, the body will gradually return to its natural hormonal rhythm. This return may involve the temporary reappearance of pre-existing conditions like acne, or experiencing symptoms such as irregular periods and mood changes.


Q: Does Laurina interact with caffeine?

A: Official drug interaction information indicates that co-administration with caffeine may potentially increase the risk of experiencing certain side effects.


Q: How does being on Laurina affect routine medical procedures?

A: Official warnings state that the medicine should be temporarily suspended prior to and shortly following major surgery that involves prolonged periods of immobilization. This is due to the increased risk of blood clots.


Q: Is there specific guidance in official documents regarding use with grapefruit products?

A: Official drug interaction information advises users to avoid consuming grapefruit or grapefruit juice while taking the medicine.


Q: What should a person do if they suspect an interaction with Laurina?

A: If a serious interaction is suspected (e.g., severe vomiting/diarrhea, signs of a serious adverse reaction) or if the medicine's effectiveness is compromised, official guidance includes the need to consult a healthcare professional immediately.


Q: Is blurred vision sometimes reported as an effect of Laurina?

A: Official safety documentation notes the possibility of vision changes or blurred vision. Users who wear contact lenses may also experience intolerance or discomfort while using the medicine.


Q: Can Laurina cause sun sensitivity?

A: Official warnings state that the medicine may cause darkening of facial skin known as melasma. The label suggests minimizing sun exposure and using sun protection, as the medicine can make the skin more sensitive to the sun.


Q: How is the dose of Laurina generally determined?

A: The dose for Laurina is fixed for the product's formulation (e.g., 0.15 mg/0.03 mg) and is taken daily in a specific cyclical regimen. The specific dose is determined by the manufacturer's formulation, not by the individual patient.


Q: Are there any specific lifestyle changes that commonly go along with taking Laurina?

A: Official warnings state that cigarette smoking should be avoided, particularly for women over 35. Smoking is linked to a significantly increased risk of serious cardiovascular events, such as stroke and heart attack, while using hormonal contraception.

How should Laurina be stored and disposed of?

Official Storage and Disposal Requirements

Laurina (desogestrel/ethinyl estradiol) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The regulatory allowance for brief excursions is 15 C to 30 C (59 F to 86 F).

Protection and Handling: The medicine must be kept in its original container or blister pack and protected from excessive heat and moisture to maintain stability. The product must be stored out of the reach of children.

Disposal: Unused or expired Laurina must be disposed of according to local guidelines. The official preferred method is using a drug take-back program. If a take-back program is unavailable, disposal should follow federal household trash guidelines: mixing the tablets with an undesirable substance (like coffee grounds or dirt) in a sealed bag before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laurina found in:

A-Z Index: